Immediately after going to Abington High School, Dr. Rosenwald began his healthcare schooling at PSU in 1973. He excelled a business and was particularly fascinated with economics and finance. He was a member of Beta Gamma Sigma, the business school’s honors society. In 1977, he graduated with his Bachelors degree in Finance. In spite of his abilities and curiosity about business, Lindsay Rosenwald had always aspired to be a medical professional.

His first step in completing his dream was to get accepted to a medical college, which he did, and started to attend Temple University. After completing his research at Temple, he was accepted into an internship at Abington hospital. After completing his internship, he functioned as being a healthcare professional in his private practice for 2.5 years. Even though he enjoyed practicing medicine Dr. Lindsay Rosenwald seemed as if something was lacking. He made the decision he needed to blend his 2 pursuits, business and medicine, and locate a career that would let him pursue those interests.

Rosenwald left his private practice in 1986 to head to Wall Street where he got on a position as a Physician / Analyst, a really unique placement with just a few individuals doing it at that time. In spite of the belief that doctors do not make good investors, Dr Rosenwald excelled at this placement. He had an eagerness for increasing investment finance available to the health care industry and that is largely why he worked there. People admired him and honored his thoughts and knowledge. Even though he missed dealing with patients, he understood this was exactly where he belonged. During this time, he also worked for DH Blair and Company, a private investment company, as the managing director of corporate finance. Eventually, he left D.H. Blair and Company to focus on a new project and company.

Lindsay Rosenwald , founder of Paramount Biotech, made it successful by acquiring other biotech organizations and making them a part of his portfolio. The organization has financed more than two dozen businesses within the last 3 years. He can make these acquired organizations successful simply because he focuses on both improving the corporate framework of the company, in addition to increasing the analysis part.. Now, Paramount Capital is made up of a lot of companies. These companies include Paramount Biosciences, which creates and supports new biotechnology businesses, Paramount Corporate Development, which actively works to build the Paramount Corporation in addition to produce new medicines, and Paramount BioCapital, a broker-dealer that has raised over $950 billion in revenue since it started. The businesses that Rosenwald controls have licensed or purchased over 100 experimental stage drugs.

Among the most notable accomplishments for Rosenwald is setting the record for the speediest acceptance of a new medication to market. In a little over 24 months, Arsenic Trioxide was researched, tested, approved and brought to market for treating leukemia. It is credited with saving 1000s of lives in the decade it has been on the market.

Lindsay Rosenwald has been groundbreaking with the companies he has created. In one of the very best reverse takeovers of them all, his company, Cougar Biotechnology, sold for more than $1 billion to Johnson and Johnson, despite merely having a single drug with stage two clinical data. He has also started the very first publicly traded stem cell organization, gene therapy company, and cancer vaccine company. Under Rosenwald’s control, his businesses have developed numerous innovative medicines, including Peramivir for H1N1 Influenza, Fanapt for schizophrenia, Savella for fibromyalgia, and Trisinox for acute leukemia. He is also accountable for the first successful anti-obesity drug developed in the USA market in 30 years.

Dr Lindsay Rosenwald is the world’s most prolific entrepreneur in the history of the biotechnology industry. People attribute the success of biotechnology on Wall Street in the last thirty years to him. His personal assets total greater than $600 million. In 2002, Rosenwald topped the list of Genetic Engineering News’s 100 Molecular Millionaires.